Aripiprazole acts as a selective dopamine D2 receptor partial agonist

  title={Aripiprazole acts as a selective dopamine D2 receptor partial agonist},
  author={Martyn D. Wood and Charles A. Reavill},
  journal={Expert Opinion on Investigational Drugs},
  pages={771 - 775}
  • M. Wood, C. Reavill
  • Published 15 May 2007
  • Psychology, Biology, Medicine
  • Expert Opinion on Investigational Drugs
Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacological profile. It has been claimed that partial agonism of the dopamine D2 and 5-HT1A receptors and antagonism of the 5-HT2 receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-HT stabiliser. However, recent studies have questioned the role of the 5-HT… 

Aripiprazole in combination with other antipsychotic drugs may worsen psychosis

Clinicians should be cautious when adding aripiprazole to patients under treatment with dopamine antagonists with a high affinity for D2 and D3 receptors, considering that the dopaminergic effect of aripIPrazole may have induced a worsening of psychotic symptoms.

Interaction of Dopamine D2 and 5-HT1A Receptor Partial Agonism on Antipsychotic Efficacy

The 5-HT1A partial agonist activity of aripiprazole and perospirone could cause differing levels of PANSS score improvement, dependent on the HTR1A polymorphism, and the strong interaction with the dopamine D2 receptors highlights the issue that the antipsychotics used are not exclusively acting on the 5- HT1A receptors.

Aripiprazole: a review of its use in the management of schizophrenia in adults.

Oral aripiprazole provides an effective and well tolerated treatment alternative for the acute and long-term management of patients with schizophrenia and may provide a more cost-effective treatment option compared with other atypical antipsychotic agents.

State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia

It is found that administration of aripiprazole acutely or after 1 or 7 days of withdrawal from 21-day repeated treatment led to a decrease in the number of spontaneously active dopamine neurons in MAM rats but not in controls, which may underlie the acute psychotic state often observed with switching to this treatment.

Antipsychotic drug action: antagonism, inverse agonism or partial agonism.

  • P. Strange
  • Psychology, Medicine
    Trends in pharmacological sciences
  • 2008

The role of agonistic/antagonistic activity in the development of psychotropic effects of antipsychotics

It can be assumed that modulation of presynaptic regulation is one of the promising directions for the development of antipsychotic drugs of future generations, because direct antagonistic activity is «alien» to physiological mechanisms of neurotransmission modulation.

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study

Findings may help physicians in choosing relevant ways to use aripiprazole and highlight areas where more research is needed to widen the evidence base.

Aripiprazole Offsets Mutant ATXN3-Induced Motor Dysfunction by Targeting Dopamine D2 and Serotonin 1A and 2A Receptors in C. elegans

The efficacy of aripiprazole to reduce motor dysfunction in vivo is confirmed, using a Caenorhabditis elegans model of MJD, and the drug targets required for its positive action against mutant ATXN3 pathogenesis are unveiled, strengthening the relevance of dopaminergic and serotoninergic signaling modulation against mutant Ataxin-3-mediated pathogenesis.



Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology

The results support the hypothesis that the unique actions of aripiprazole in humans are likely a combination of ‘functionally selective’ activation of D2 (and possibly D3)-dopamine receptors, coupled with important interactions with selected other biogenic amine receptors—particularly 5-HT receptor subtypes (5-HT1A, 5- HT2A).

Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors

These results, together with previous studies demonstrating partial agonist activity at serotonin 5-hydroxytryptamine (5-HT)1A receptors and antagonist activity at 5-HT2A receptors, support the identification of aripiprazole as a dopamine-serotonin system stabilizer.

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.

Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.

The aim of the present study was to characterise the interaction of APD with a variety of monoamine receptors in terms of both affinity and efficacy.

Aripiprazole: profile on efficacy and safety

Early data suggest that aripiprazole may induce reductions in plasma prolactin, as well as in plasma glucose and lipid profiles, and results also support the proposition that it may lead to reductions in corrected QT interval and have minimal drug interactions.

Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways

The results are consistent with the hypothesis that aripiprazole is a functionally selective D2 ligand rather than a simple partial agonist, and may be useful in understanding the novel clinical actions of this drug.

Serotonin receptors : their key role in drugs to treat schizophrenia

Mechanism of Action of Aripiprazole Predicts Clinical Efficacy and a Favourable Side-Effect Profile

Aripiprazole shows a favourable preclinical efficacy and side-effect profile compared to a typical antipsychotics, which may result from its high affinity partialagonist activity at D2 and 5- HT1A receptors and its antagonism of 5-HT2A receptors.

Attenuation of haloperidol‐induced catalepsy by a 5‐HT2C receptor antagonist

The data suggest a role for 5‐HT2C receptors in the anticataleptic action of SB‐228357, and suggest that atypical neuroleptics produce fewer extrapyramidal side‐effects (EPS) than typical neurolePTics.

The Differential Effects of Atypical Antipsychotics on Prolactin Elevation Are Explained by Their Differential Blood-Brain Disposition: A Pharmacological Analysis in Rats

Results indicate that dissociation between central and peripheral D2 receptor occupancy is a major determinant of the degree of prolactin elevation observed at therapeutic doses.